Dear Editor, Treatment strategies for newly diagnosed mantle cell lymphoma (MCL) vary substantially according to patient age, performance status, and comorbidities [1]. Intensive cytarabine-based regimens followed by upfront autologous stem cell transplantation (ASCT) has been preferred for younger or fit patients, while less intensive ones for older or frail patients. Rituximab maintenance therapy is recommended for both groups across major guidelines [2].